Compare Monster Beverage Corp (MNST) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Summit Therapeutics Inc — how do they compare? Monster Beverage Corp trades at $42.96 (market cap $84.53B), while Summit Therapeutics Inc trades at $17.52 (market cap $13.79B). The key difference: Monster Beverage Corp is far larger — about 6.1× Summit Therapeutics Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| MNST | SMMT | |
|---|---|---|
Market Cap | $84.53B | $13.79B |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $26.38 |
52-Week Low | $31.41 | $12.43 |
Enterprise Value | $82.83B | $13.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.15, down 1.53% on the day, following a recent 2-for-1 stock split completed August 11, 2026. The stock shows strong fundamental performance with revenue growing from $6.3B in 2022 to $8.3B in 2025, while net income expanded to $1.91B. Technical indicators present a mixed picture with bullish oscillators but bearish moving averages, creating uncertainty in the near-term direction. Analyst consensus remains positive with 51% buy ratings and a $51.10 price target representing 18% upside potential.
MNST offers compelling growth prospects driven by 20%+ revenue growth and expanding international presence (46% of Q2 2026 sales). However, elevated valuation multiples (P/E 39.95, P/S 9.24) and rising cost pressures present risks. The company's consistent earnings beats and strong cash flow generation support the bullish case, but investors should weigh growth potential against premium valuation in a competitive beverage market.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
